E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
NON OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10041299 |
E.1.2 | Term | Soft tissue sarcomas |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the efficacy of the combination of trabectedin and doxorubicin in comparison with doxorubicin alone in patients with advanced non operable and/or metastatic Soft Tissue Sarcomas (STS). To this end, progression free survival will be compared between both groups of treatment. |
|
E.2.2 | Secondary objectives of the trial |
- To determine activity by means of RECIST objective responses in both study arms, trabectedin/doxorubicin combination and the control arm. - To determine the tumor control (response rates plus stabilizations) in both arms of treatment. - Overall survival. - To determine activity by tissue changes applying the Choi criteria to STS (see radiological review sub study). - To determine toxicity of trabectedin/doxorubicin combination and the control arm. - To determine protein and mRNA expression of genes possibly involved in a potential profile of more favorable response or resistance to study drugs and to analyze the prognostic impact of them on predefined efficacy parameters (see translational sub study). - To evaluate genomic instability, as well as protein expression that could influence response/resistance to the study drugs and make a correlation with efficacy endpoints. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
I) Protein expression study: Identify and quantify by TMA (see procedure) from paraffin-embedded STS tumor tissue predictive factors of response to treatment with doxorubicin plus/minus trabectedin. II) Microsatellite instability analysis: -Evaluate the incidence of genetic instability in tumors from patients included in the trial, taking into account 18 MSI and EMAST markers. -Analyze the protein expression of the main proteins involved in DNA repair machinery: MLH1, MSH2, MSH6 y PMS2 associated with MDMSI; and p53, associated with EMAST. - Correlate genetic instability with response to doxorubicin and doxorubicin plus trabectedin. -Correlate genetic instability and PFS. III) DNA repair genes analysis: - Validate the molecular sensitivity signature (low BRCA1, high XPG or ERCC1 expression) obtained in the retrospective study of advanced sarcoma patients treated with trabectedin monotherapy. In this case, the correlation of these markers with clinical response to the combined treatment with doxorubicin-trabectedin will be studied, using as a control patients treated with doxorubicin alone. - Analyze the XPG Asp1104Hi polymorphism in blood samples (genotype) and in tumor samples (somatic mutations) to establish their correlation with response to trabectedin. - Correlate the molecular and genetic signature with PFS. |
|
E.3 | Principal inclusion criteria |
The patient must sign voluntarily the informed consent Aged between 18 and 70.
- Pathological diagnosis of non operable and/or metastatic soft tissue sarcoma.
- The following histological subtypes can be included:
• Undifferentiated pleomorphic sarcoma (previously, malignant fibrous histiocytoma) • Leiomyosarcoma • Angiosarcoma/ epithelial hemangioendothelioma • Liposarcoma and its variants (well differentiated, dedifferentiated, myxoid/round cells, pleomorphic) • Synovial sarcoma • Fibrosarcoma and its variants ( epithelial fibrosarcoma/low grade fibromyxoid sarcoma) • Hemangiopericytoma/solitary fibroid tumor • Neurogenic sarcoma (Malignant peripheral nerve sheath tumor (MPNST)) • Mixofibrosarcoma • Epithelioid Sarcoma • Unclassified sarcoma (spindle cell/epithelioid/pleomorphic/myxoid)
- Measurable disease, according to RECIST criteria
- Performance status 0-1 (ECOG).
- Adequate bone marrow function (hemoglobin > 10 g/dL, leukocytes ≥ 3.000/mm3, neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3). Patients with plasma creatinine ≤ 1,6 mg/dL, transaminases ≤ 2.5 times the UNL, total bilirubin ≤ UNL, CPK ≤ 2.5 times UNL, alkaline phosphatase ≤ 2.5 times the UNL are acceptable. If the increase of alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver fraction and/or 5’ nucleotidase and/or GGT must be ≤ UNL.
- Men or women of child bearing potential should be using an effective method of contraception before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative urine pregnancy test before study entry.
- Normal cardiac function with a LVEF ≥ 50% by echocardiogram or MUGA.
- It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive it is recommended to reject the existence of replicative phase (HbaAg+, DNA VHB+). If these were positives the inclusion is not recommended, remaining at investigators' discretion the preventive treatment with lamivudine. If the patient is HCV+ it could be included in the study if there are no changes in transaminases values at investigators' discretion.
|
|
E.4 | Principal exclusion criteria |
Patients presenting with any of the following criteria cannot be included in the study:
- Previous chemotherapy treatment.
- Previous radiotherapy involving the only localization(s) of measurable tumoral disease.
- Performance status ≥ 2 (ECOG).
- CNS metastases.
- Plasma bilirubin > UNL.
- Creatinine > 1.6 mg/dL.
- History of other neoplastic disease with the exception of basalioma or in situ cervical cancer adequately treated.
- Significant cardiovascular disease (for example, dyspnea > 2 NYHA)
- Significant systemic diseases grade 3 or higher on the NCI-CTC version 3.0 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity.
- Uncontrolled bacterial, mycotic or viral infections.
- Known positive test for infection by human immunodeficiency virus (HIV) - Women who are pregnant or breast-feeding
- Psychological, familial, social or geographic circumstances that limit the patient’s ability to comply with the protocol or informed consent.
- Patients participating in another clinical trial or receiving any other investigational product. Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to inclusion.
- The following histologic subtypes are excluded: - Rhabdomyosarcoma -Ewing’s family of tumors - Desmoplastic small round cell tumor - Clear cell sarcoma - Alveolar sarcoma
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
PFS: Progression free survival |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 27 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be considered closed from a normative point of view after the data on overall survival is sufficiently prepared for its initial publication. The follow-up observations of the patients included in the trial can be maintained indefinitely. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |